An educational analysis of a published U.S. Supreme Court judgment, prepared from the client-supplied case study.
1. The question
Explore the distinction between discovering a natural organism and creating a human-made biological invention under Section 101.
2. Executive Summary
Diamond v. Chakrabarty, 447 U.S. 303 (1980), is a landmark decision in American patent law that addressed whether a living organism created through genetic engineering could qualify as patentable subject matter under Section 101 of the United States Patent Act.
The dispute arose from a patent application filed by Ananda M. Chakrabarty, a microbiologist working on genetically engineered bacteria capable of breaking down multiple components of crude oil. The invention had potential applications in bioremediation, particularly in the treatment of oil spills.
The patent examiner allowed claims directed to the process used to produce the bacteria and to an inoculum containing the bacteria with a carrier material. However, the examiner rejected the claims directed to the bacteria themselves, reasoning that living organisms were not patentable subject matter and that the organism could be considered a product of nature.
After the Patent Office Board of Appeals affirmed the rejection, the Court of Customs and Patent Appeals reversed. The Commissioner of Patents and Trademarks then sought review by the Supreme Court.
On 16 June 1980, the Supreme Court affirmed the appellate decision in a 5–4 ruling. Chief Justice Warren E. Burger delivered the majority opinion.
The Court held that a human-made microorganism could fall within the statutory categories of a “manufacture” or “composition of matter” under Section 101. The decisive consideration was that the claimed bacterium was not merely a naturally occurring organism discovered in the environment. It had been engineered to possess characteristics that distinguished it from naturally occurring bacteria, including the ability to degrade multiple components of crude oil.
The Court interpreted the statutory language broadly, while preserving the established exclusions for laws of nature, natural phenomena and abstract ideas.
The decision did not establish that every living organism, biological discovery or genetically modified product is patentable. Nor did it eliminate the other requirements for obtaining a patent. Instead, it confirmed that living status alone does not exclude a human-made microorganism from patent eligibility.
Central principle: A human-made biological invention may qualify as patent-eligible subject matter when it falls within the statutory categories and is not merely a naturally occurring phenomenon. Eligibility under Section 101 does not, by itself, establish novelty, non-obviousness, adequate disclosure or entitlement to a patent.
3. The Legal Issues Before the Supreme Court
The principal question was whether a live, human-made microorganism could constitute patentable subject matter under Section 101.
The Court considered several connected issues:
Whether the statutory terms “manufacture” and “composition of matter” were broad enough to encompass an engineered microorganism.
Whether the fact that the claimed organism was alive excluded it from patent protection.
Whether the organism was merely a product of nature or a human-made invention with distinct characteristics.
Whether earlier legislation dealing with plants and biological subject matter required a narrower interpretation of Section 101.
Whether concerns about the potential hazards of genetic engineering should influence the judicial interpretation of the statute.
The Court treated the principal question as one of statutory interpretation. It examined the words Congress had enacted and the established judicial exceptions to patent-eligible subject matter.
4. Holding and Ratio Decidendi
The Supreme Court held that a live, human-made microorganism could constitute a “manufacture” or “composition of matter” under Section 101.
The Court concluded that the engineered bacterium was not merely a product of nature because it possessed characteristics that distinguished it from naturally occurring bacteria. The Court therefore affirmed the decision of the Court of Customs and Patent Appeals.
Ratio decidendi
The ratio decidendi is that a human-made microorganism is not excluded from patent-eligible subject matter solely because it is alive. Where the claimed organism is a qualifying manufacture or composition of matter created through human ingenuity, it may fall within Section 101, subject to the statutory requirements and established exclusions.
The decision does not establish that every biological organism or genetically engineered product is patentable. It addresses the eligibility of the claimed engineered microorganism under the statutory provision before the Court.
5. Conclusion
Diamond v. Chakrabarty established that the fact that an organism is alive does not, by itself, exclude it from patent-eligible subject matter under Section 101.
The Supreme Court interpreted the statutory categories broadly and concluded that the engineered bacterium before it was a human-made composition with characteristics distinguishing it from naturally occurring bacteria.
The ruling became a foundational authority for biotechnology patent law because it allowed the existing statutory framework to encompass qualifying inventions developed through genetic engineering, even though that technology had not been specifically anticipated when the relevant statutory language was enacted.
Its practical significance remains substantial, but its limits must be understood carefully. A human-made biological product must still satisfy the other applicable patent requirements, and naturally occurring materials remain subject to the product-of-nature doctrine.
For corporate counsel, patent attorneys and biotechnology businesses, the enduring lesson is that the patentability of biological technology depends on the actual claimed invention, the nature of the human intervention, the relevant legal exceptions and the evidence supporting the claim.
The lasting principle of *Chakrabarty* is that patent law can accommodate new scientific technologies through broad statutory language, but eligibility remains dependent on the substance of the claimed invention—not simply the fact that it is new to its discoverer or useful in commerce.
6. Read the full analysis
Diamond v. Chakrabarty (1980): Patenting engineered organisms